Previse
Previse: Pioneering early cancer detection through affordable, accurate biomarker technology, starting with esophageal cancer.
Founded
2018Previse: Pioneering early cancer detection through affordable, accurate biomarker technology, starting with esophageal cancer.
Previse was founded with the core mission of saving lives through the earlier detection and prevention of cancer, beginning with esophageal cancer. The company leverages decades of research from the GI Early Detection Biomarker Lab and funding from the National Institutes of Health (NIH) to develop its technology. Previse offers Esopredict™, a molecular test that provides personalized guidance for Barrett’s esophagus surveillance and treatment decisions. Their focus is on utilizing biomarker technology to give patients and healthcare providers timely and accurate information.
Notable affiliated individuals include researchers from the GI Early Detection Biomarker Lab, whose work underpins Previse's technology. The company's key achievements include securing NIH grants and developing a market-ready product, Esopredict™, which is available through licensed healthcare providers. Previse's impact lies in its potential to significantly improve cancer outcomes by enabling earlier detection and more precise treatment strategies, thereby addressing a critical need in oncology diagnostics.
Companies similar to Previse include Episteme Prognostics, Predictive Biosciences, Lucid Diagnostics and BioDetego.
Previse was founded in 2018.
Previse's headquarters is located in Baltimore, MD, US.
Previse's most recent funding round was for $1.8M (USD) in October 2023.
As of Oct 11, 2023, Previse has disclosed funding of $6.3M (USD). Undisclosed round amounts are excluded.
Previse has 12 employees as of Feb 4, 2024.
BioDetego
